kw.\*:("enhanced disease")
Results 1 to 5 of 5
Selection :
Biological challenges and technological opportunities for respiratory syncytial virus vaccine developmentGRAHAM, Barney S.Immunological reviews. 2011, Vol 239, pp 149-166, issn 0105-2896, 18 p.Article
Transcriptional reprogramming regulated by WRKY18 and WRKY40 facilitates powdery mildew infection of ArabidopsisPANDEY, Shree P; ROCCARO, Mario; SCHÖN, Moritz et al.Plant journal. 2010, Vol 64, Num 6, pp 912-923, issn 0960-7412, 12 p.Article
The conserved Xanthomonas campestris pv. vesicatoria effector protein XopX is a virulence factor and suppresses host defense in Nicotiana benthamianaMETZ, Matthew; DAHLBECK, Douglas; MORALES, Christina Q et al.Plant journal. 2005, Vol 41, Num 6, pp 801-814, issn 0960-7412, 14 p.Article
Maternal antibodies by passive immunization with formalin inactivated respiratory syncytial virus confer protection without vaccine-enhanced diseaseKWON, Young-Man; HYE SUK HWANG; MOORE, Martin L et al.Antiviral research. 2014, Vol 104, pp 1-6, issn 0166-3542, 6 p.Article
Vaccination with recombinant modified vaccinia virus ankara expressing bovine respiratory syncytial virus (bRSV) proteins protects calves against RSV challengeANTONIS, Adriaan F. G; VAN DER MOST, Robbert G; SUEZER, Yasemin et al.Vaccine. 2007, Vol 25, Num 25, pp 4818-4827, issn 0264-410X, 10 p.Article